MassDevice6d
Medtronic has positive TAVR results in small aortic annulus patients
Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...
GlobalData on MSN6d
Medtronic announces two-year trial outcomes of Evolut TAVR
Medtronic has announced the SMART trial’s two-year outcomes of Evolut TAVR for aortic stenosis (AS) and small aortic annulus.
Zacks.com on MSN6d
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.
PharmiWeb6d
SMART Trial two-year data continues to demonstrate…
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
Kalkine Media6d
Medtronic’s SMART Trial Shows Evolut TAVR Outperforms SAPIEN in Key Long-Term Outcomes
Highlights,Evolut TAVR demonstrated significantly lower rates of bioprosthetic valve dysfunction (BVD) compared to SAPIEN at ...
Nasdaq6d
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
The two-year results highlighted the continued superior performance of the Evolut TAVR valve in patients with a small aortic annulus. These results will be followed to assess long-term outcomes.
BioWorld6d
Medtronic sees SMART TAVR results in small aortic annulus patients
Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli.